Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-15 (Canceled)

16. (New) A compound having the general formula I:



I

wherein

R1, R2, R3, R4, R5, are each independently selected from H, halogen, NO_2, CN, C_{1-6} alkyl, CF_3 aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, OCF_3, OR18, SR18, OC_{1-6} alkyl, OC_{2-6} alkylNR18R19, Oaryl, Oheteroaryl, Ocycloalkyl, Ocycloheteroalkyl, OC_{1-6} alkylaryl, OC_{1-6} alkylheteroaryl, OC_{1-6} alkylcycloalkyl, OC_{1-6} cycloheteroalkyl, CO_2R18, C_{1-6} alkylCO_2R18, CONR18R19, C_{1-6}alkylCONR18R19, NR18R19, C_{1-6} alkylNR18R19, NR20C_{1-6} alkylNR18R19, C_{1-6}alkylNR20C_{1-6} alkylNR18R19, NR18C0R19, C_{16} alkylNR18COR19, C_{1-6} alkylNR20CONR18R19, NR20CONR18R19, C_{1-6} alkylNR18SO_2R19, NR18SO_2R19;

R18, R19 are each independently selected from H, C_{1-4} alkyl, C_{1-4} alkyl cycloheteroalkyl, aryl, heteroaryl, C_{1-4}alkyl aryl, C_{1-4}alkyl heteroaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21;

R20, R21 are each independently selected from H, C_{1-4}alkyl;

R6 is selected from H, C_{1-4} alkyl,

R7 is selected from H, C_{1-4} alkyl, SH, CN;

R8 is selected from OR9, NR9R10;

R9, R10 are each independently selected from H, C_{1-4} alkyl, C_{1-4} alky1CO_2H, C_{1-4} alkyl cycloheteroalkyl, aryl, heteroaryl, C_{1-4} alkyl aryl, C_{1-4} alkyl heteroaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR11;

R11 is selected from H, C_{1-4} alkyl.

17. (New) A compound according to claim 16 wherein:

R1, R2, R3, R4 and R5 are each independently selected from H, OH, OC_{1-4} alkyl, OC_{1-4} alkylaryl, C_{1-4} alkyl, halogen;

R6 is selected from H, C_{1-4} alkyl,

R7 is selected from H, C_{1-4} alkyl, SH, CN;

R8 is selected from OH, NR9R10;

R9, R10 are each independently selected from H, C_{1-4} alkyl, C_{1-4} alkylCO_2H.

18. (New) A compound having the general formula II:



II

wherein

Rl, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are each independently selected from H, halogen, NO_2, CN, C_{1-6} alkyl, CF_3, aryl, heteroaryl, cylcoalkyl, cycloheteroalkyl, OCF_3, OR18, SR18, OC_{1-6} alkyl, OC_{2-6} alky1NR18R19, Oaryl, Oheteroaryl, Ocycloalkyl, Ocycloheteroalkyl, OC_{1-6} alkylaryl, OC_{1-6} alkylheteroaryl, OC_{1-6} alkylcycloalkyl, OC_{1-6} cycloheteroalkyl, CO_2R18, C_{1-6} alkylCO_2R18, CONR18R19, C_{1-6} alkylCONR18R19, NR18R19, C_{1-6} alkylNR18R19, NR20C_{1-6} alkylNR18R19, C_{1-6} alky1NR20C_{1-6} alkylNR18R19, NR18COR19, C_{1-6} alkylNR18COR19, C_{1-6} alky1NR20CONR18R19, NR20CONR18R19, C_{1-6} alky1NR18SO_2R19, NR18SO_2R19;

R18, R19 are each independently selected from H, C_{1-4} alkyl, C_{1-4} alkyl cycloheteroalkyl, aryl, heteroaryl, C_{1-4} alkyl aryl, C_{1-4} alkyl heteroaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21;

R20, R21 are each independently selected from H, C_{1-4}alkyl;

R11, R12 are each independently selected from H, C_{1-4} alkyl, halogen, OC_{1-4} alkyl.

19. (New) A compound according to claim 18 wherein

R1, R2, R3, R4, R5, R6, R7, R8, R10 are each independently selected from H, C_{1-4} alkyl, OC_{1-4} alkyl, CO_2H, CN;

R11, R12 are each independently selected from H, C_{1-4} alkyl.

20. (New) A pharmaceutical composition comprising

(a) one or more compounds according to claim 16;

(b) a pharmaceutically acceptable diluent.

21. (New) A pharmaceutical composition comprising

(a) one or more compounds according to claim 17;

(b) a pharmaceutically acceptable diluent.

22. (New) A pharmaceutical composition comprising

(a) one or more compounds according to claim 18;

(b) a pharmaceutically acceptable diluent.

23. (New) A pharmaceutical composition comprising

(a) one or more compounds according to claim 19;

(b) a pharmaceutically acceptable diluent.

24. (New) A method for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compounds according to claim 16.

25. (New) A method for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compounds according to claim 17.

26. (New) A method for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compounds according to claim 18.

27. (New) A method for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compounds according to claim 19.

28. (New) A method for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compositions according claim 20.

29. (New) A method for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compositions according claim 21.

30. (New) A method for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compositions according claim 22.

31. (New) A method for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compositions according claim 23.

32. (New) A method according to claim 24 wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.

33. (New) A method according to claim 25 wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.

34. (New) A method according to claim 26 wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.

35. (New) A method according to claim 27 wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.

36. (New) A method according to claim 28 wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.

37. (New) A method according to claim 29 wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.

38. (New) A method according to claim 30 wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.

39. (New) A method according to claim 31 wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.